Autolus publishes Annual Report

RNS Number : 4668I

Syncona Limited

26 November 2018

 

Syncona Limited

Autolus publishes Annual Report

26 November 2018

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. 

The announcement can be found below and the annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

 [ENDS]

Enquiries

Syncona Ltd

Annabel Clay

Tel: [phone]

Tulchan Communications

Martin Robinson

Lisa Jarrett-Kerr

Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com 

About Syncona

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

About Autolus

Autolus is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.

Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, November 23, 2018 -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission.  The annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

 # #

Investor contact:

S.A. Noonan Communications

Susan A. Noonan

[phone]

[e-mail]

International Media Contact:

JW Communications

Julia Wilson
[phone]

[e-mail]

U.S. Media Contact:

Rx Communications Group, LLC

Paula Schwartz
+ 1-917-322-2216

[e-mail]

 

END

 

 

PFUGCBDBBUDBGIL